Trump's Marijuana Rescheduling Push Is Back in Focus. Is Tilray Stock Finally a Buy?

A federal appeals court allowed the Trump administration's marijuana rescheduling process to continue, preserving a potential path for cannabis to move from Schedule I to Schedule III, though underlying legal challenges remain unresolved. Tilray reported fiscal 2026 revenue of $915 million, 34% growth in international medical-cannabis revenue, roughly $235 million of cash and securities, and net debt reduced to $700,000; it forecasts fiscal 2027 adjusted EBITDA of $68 million-$75 million. Rescheduling could expand Tilray Medical's eventual U.S. opportunity, but U.S. multistate operators may see more immediate benefits, including potentially improved federal tax treatment.

Analysis

The cleanest economic exposure is not TLRY but U.S. multistate operators (GTBIF, CURLF, TCNNF, VRNOF): removal of Section 280E restrictions would convert currently nondeductible operating costs into tax deductions, materially lifting cash tax conversion and free cash flow without requiring incremental unit growth. This can drive rapid deleveraging and equity re-rating over 1-3 quarters, particularly for operators with durable state-level scale. TLRY's benefit is less immediate because its U.S. option value requires additional regulatory, product-approval, and commercialization steps; its valuation will therefore remain more sensitive to execution in beverage, wellness, and international medical channels.

TLRY's diversified revenue base reduces binary policy risk, but it also dilutes the cannabis multiple investors are seeking. The key underwriting issue is EBITDA quality: acquisitive beverage and hospitality revenue can add sales while carrying lower margins, working-capital needs, and integration risk. A sustained valuation re-rate requires evidence that fiscal-2027 EBITDA guidance converts into operating cash flow after capex, lease obligations, interest, and acquisition-related costs—not simply a regulatory headline.

Near term, legal-process headlines can produce sharp retail-driven moves in TLRY, while the 1-3 month catalyst path is formal agency timing and clarity on tax implementation. The contrarian view is that the initial sector reaction may be too broad: a rescheduling outcome can be highly valuable for profitable U.S. operators yet only modestly change TLRY's next-twelve-month earnings. Conversely, a delayed process should hurt the most policy-dependent and levered operators disproportionately, creating a relative-value opportunity rather than invalidating the long-term medical-cannabis theme.

Falsify the MSO-over-TLRY thesis if tax authorities explicitly preserve 280E treatment following rescheduling, if a final rule faces an injunction, or if MSOs fail to show cash-tax relief in the first two reported quarters after implementation. Falsify a cautious TLRY stance if international medical growth accelerates while EBITDA margin and recurring free-cash-flow conversion improve materially without further dilution or leverage.

Key Decisions for Investors

• Express reform exposure through a 3-6 month pair: long GTBIF and CURLF, short TLRY in equal beta-adjusted dollars. The trade targets superior cash-tax sensitivity at U.S. MSOs; exit or reduce if formal tax guidance does not support 280E relief or if the pair underperforms by 15% following a favorable final rule.
• Do not chase TLRY on procedural legal headlines. Establish a long only after the next earnings release confirms fiscal-2027 EBITDA guidance with positive operating cash flow after working capital and no material increase in net leverage; use a 15-20% downside stop tied to failed guidance or equity issuance.
• For tactical event exposure, prefer defined-risk calls on TLRY only around a clearly dated agency decision, while maintaining the MSO equity basket as the fundamental exposure. Size premium at risk assuming a delay can erase most headline-driven gains within days.
• Monitor MSO cash-tax accruals, free-cash-flow guidance, and debt spreads each quarter. Upgrade the long basket if management quantifies tax savings and directs them to debt reduction or buybacks; avoid operators using the windfall primarily for aggressive M&A.